Back to Stocks

NAGE

Niagen Bioscience, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Niagen Bioscience is executing a decisive strategic pivot toward a lean, high-margin biotech model. By divesting its non-core analytical reference standards segment, the company has streamlined its operational footprint to focus exclusively on its proprietary Niagen ecosystem.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative, Niagen faces severe structural vulnerabilities. The company's reliance on a single supplier, W.R. Grace, for its critical raw material creates a single point of failure that could halt production entirely.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every NAGE filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a crossroads between strategic optimization and operational instability. The divestiture of the analytical segment and the resulting $4.8 million gain provided a temporary boost to net income, but the underlying core business is struggling with rising customer acquisition costs and a precarious supply chain. The shift toward e-commerce is a positive trend, yet it is offset by a worrying reversal in operating cash flow. Investors must weigh the potential of the pharmaceutical pipeline and the strength of the current cash balance against the looming risks of single-source dependency and unresolved legal challenges. The company's ability to transition from a niche supplement provider to a dominant longevity player depends on whether it can stabilize its cash flow and diversify its supply chain before its current liquidity cushion is eroded by legal costs or operational failures.

Selected Quarter

Core Takeaway

Niagen is transitioning to a pure-play NAD+ company with a strong cash position, but deteriorating operating cash flow and single-source dependency create significant risk.

Investor Lens

The trade-off is between the high-upside potential of a pharmaceutical breakthrough versus the immediate risk of a supply chain or regulatory collapse.

Watch Next

Quarterly operating cash flow trends and the outcome of the FDA lawsuit regarding NMN classification.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.22Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%
bullishMay 6

Sold non-core analytical segment for $6.0 million to focus on core NAD+ business.

divestiture
70%
bearishMay 6

Operating expenses rose 27% YoY, with marketing now consuming 31% of total sales.

margin compression
40%
bullishMay 6

Expanded share repurchase program to $20 million, repurchasing $2.4 million in Q1.

buyback
60%
neutralMay 6

Net income grew to $6.3 million, though heavily influenced by a one-time $4.8 million divestiture gain.

earnings beat
30%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a company at a crossroads between strategic optimization and operational instability. The divestiture of the analytical segment and the resulting $4.8 million gain provided a temporary boost to net income, but the underlying core business is struggling with rising customer acquisition costs and a precarious supply chain. The shift toward e-commerce is a positive trend, yet it is offset by a worrying reversal in operating cash flow. Investors must weigh the potential of the pharmaceutical pipeline and the strength of the current cash balance against the looming risks of single-source dependency and unresolved legal challenges. The company's ability to transition from a niche supplement provider to a dominant longevity player depends on whether it can stabilize its cash flow and diversify its supply chain before its current liquidity cushion is eroded by legal costs or operational failures.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.